Novel immune checkpoint targets beyond PD-1 and CTLA-4 in solid tumors

This week’s podcast from VJOncology brings you the latest updates on novel checkpoint inhibitors that target LAG-3, TIGIT, and TIM3 in solid tumors. Our panel of experts share the latest findings from their clinical trials that tested the efficacy of different immune checkpoint inhibitors in neoplastic tumors.

Myriam Chalabi from the Netherlands Cancer Institute shares results from the NICHE-2 and NICHE-3 trials on MMR-deficient colon cancer, and Girish Kulkarni from the University of Toronto discusses the cohort C section of the KEYNOTE-057 trial, followed by the potential role of TIGIT/LAG-3 inhibition for urothelial carcinoma treatment. Ghassan Abou-Alfa from the Memorial Sloan Kettering Cancer Center shares results from different trials on anti-TIGIT therapies in hepatocellular carcinoma. Diwakar Davar from the University of Pittsburgh School of Medicine concludes with main findings from the AMBER trial on cobolimab for the treatment of non-small cell lung cancer.